Alkermes narcolepsy drug shows positive phase 2 trial results

The report, published August 24, says Alkermes’ narcolepsy drug delivered positive results in a Phase 2 trial. The available report does not provide the study’s endpoint data, effect size, safety findings, patient count, or timing for the next development step.

The asset adds to the pipeline of ALKS, whose FY 2025 revenue was $1.5B, down 5.2% YoY, with a 16.4% net margin and $1.43 diluted EPS. The concrete mechanism for the stock is therefore pipeline value: a successful program could broaden the company’s future revenue base, while the current operating figures show that the market still has an established commercial business against which to measure the asset.

The next catalysts are fuller Phase 2 data, management’s comments on durability and safety, and any decision to advance the program into late-stage testing. The missing trial details leave open how differentiated the drug is, how large the addressable opportunity could be, and how much development and regulatory work remains.